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There has been an age-long controversy on whether white coat hypertension (WCH) is associated with end organ damage or not. 
Hence, the presence of left ventricular hypertrophy was assessed in individuals with WCH. This study determined the association 
between WCH and left ventricular hypertrophy among adult Nigerians. A total of 88 participants consisting of 44 patients with 
WCH and 44 age and sex-matched normotensive controls were studied. They all underwent 24-hour ambulatory blood pressure 
measurement and echocardiography. Thirty-one (70.5%) females were in each group. The mean body mass index of patients 
(26.4 ± 4.5kg/m2) was significantly higher than that of the controls (23.8 ± 4.3kg/m2). Twenty-four of 44 patients and 19 of 44 
controls had left ventricular hypertrophy; (chi square=1.137, p-value=0.286). There is high but similar prevalence of LVH among 
participants with WCH and normotension among adult Nigerians. Hence, there is need to assess every patient with WCH for the 
presence of LVH and to be followed up for the development of other cardiovascular risk factors. 
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INTRODUCTION 
 
There has been age-long controversy on whether white coat 
hypertension (WCH) is associated with target organ damage 
or not. Recent studies revealed the presence of increased end 
organ damage in individuals with WCH whereas older studies 
showed no evidence of target organ damage.(Staessen et al., 
1999, Pierdomenico et al., 1995, Parati et al., 2000b, Cuspidi 
et al., 2018). Although cardiovascular (CV) events and target 
organ damage are not as common in white‐coat hypertension 
(WCH) compared with sustained hypertension, it is yet to be 
fully explained whether WCH is associated with an increased 
CV risk and target organ damage compared with 
normotension among the Nigerian population. It has however 
been documented that WCH is associated with subclinical 
organ damage as indicated by elevated left ventricular (LV) 
mass index (LVMI). (Androulakis et al., 2017, Anstey et al., 
2018). However, appropriate management of systemic 
hypertension (SH) begins with early diagnosis and 
identification of individuals at risk by detection of early 
makers of the disease. Ambulatory blood pressure monitoring 
(ABPM) is considered the best method to detect blood 
pressure (BP) fluctuations and the most reliable method of 
diagnosing white coat hypertension (WCH).(Pickering, 1998). 
Recent researches have concluded that ABPM is a better 
predictor of cardiovascular (CV) mortality than office-
measured pressure.(Banegas et al., 2018, Huang et al., 2017). 
ABPM can monitor BP for a 24-hour period while providing 
more detailed BP measurements including the day-time and 
night-time BP.  
 Left ventricular hypertrophy (LVH) is an early maker of 
hypertensive cardiovascular       disease.(Giles et al., 2005). 
Hence, the presence of LVH in any patient is a strong and 
independent risk factor for subsequent cardiovascular event. 
(Ferdinand and Maraboto, 2019, Cipriano et al., 2001). 
Nevertheless, LVH is a common and potentially modifiable 
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absence of symptoms for many years before the development 
of cardiovascular events.(Lorell and Carabello, 2000). In 
contemporary clinical practice and population studies, the 
diagnosis of LVH depends predominantly on 
echocardiographic measurements. 
  A recent study in Nigeria showed high prevalence of 
WCH in the study population.(Dele-Ojo et al., 2019). Also, 
some studies have been done in Nigeria on the association 
between end organ damage and systemic hypertension 
(Nelissen et al., 2014, Saidu et al., 2018). However, to the best 
of our knowledge, none has been done to determine the 
association between WCH and LVH. In Nigeria, there is 
currently no study linking WCH and left ventricular 
hypertrophy. Hence, this study determined the association 
between WCH and LVH among adult Nigerians. 
 
 
MATERIALS AND METHODS 
 
Study design and area: This research was a cross-sectional 
survey conducted in the Medical Outpatient Department 
(MOPD) of the University of Ilorin Teaching Hospital 
(UITH), Ilorin, Kwara State in North-central Nigeria.  
 
Inclusion and Exclusion criteria: Patients were adults with 
WCH diagnosed using ABPM while controls were 
normotensive sex and age-matched adults. Those with 
suspicion of secondary hypertension, renal disease, diabetes 
mellitus, chronic heart failure or other forms of cardiovascular 
diseases and pregnant women were excluded from both study 
groups. 
 
Study protocol: The study population consisted of 88 
individuals that included 44 patients with WCH and 44 
normotensive controls; seen at the MOPD at the UITH during 
a 12‐month period. All study participants had complete 
physical examination, standard 12‐lead electrocardiography, 
ABPM and echocardiography.  All eligible participants were 
informed about the study, and informed consent was obtained. 
Thereafter, each participant completed a self-administered 
questionnaire. 
 
Sample technique: Consecutive sampling was used where 44 
patients with WCH and 44 age and sex-matched participants 
were recruited.  
 
Office BP Measurements: Office BP was taken in the office 
after a 5-minute rest with the participant seated, office BP 
measurements were taken with a mercury 
sphygmomanometer, and were taken on the bare arm that was 
supported and held at heart level. The mean of three (3) 
measurements was used as the office BP. 
 
ABPM measurements: ABPM was performed using an 
oscillometric device (CONTEC®), which was revalidated 
regularly against a mercury sphygmomanometer. Thereafter, 
The ABPM was attached to each participant with the day-time 
measurements taken every 30 minutes as from 7 a.m. to 10.00 
p.m. and thereafter, ABPM reads every one hour from 10:00 
p.m. to 7.00 a.m. The participants were all instructed to engage 
in their usual activities throughout the day. The appropriate 
cuff for arm circumference was placed on the non-dominant 
arm and the participants were instructed to keep their arm 
extended at cardiac level during automatic BP measurements. 
The guidelines of the European Society of Hypertension 
(ESH) for the treatment of hypertension’s cut-off limits was 
applied, thus:  normal day-time, mean 24-hour ABPM and 
night-time ABPM were 135/85mmHg, 130/80mmHg and 
120/70mmHg respectively. (Mancia et al., 2013). 
 
Participants’ categorization into subgroups on the basis of 
office BP and ABPM. 
1. Normotensive individuals by both office and ABPM 
methods were referred to as truly normotensive 
individuals.  
2. Individuals who were hypertensive by both methods were 
referred to as those with true hypertension.  
3. WCH was defined as office BP <140/90mmHg despite a 
normal day-time ABPM <135/85mmHg.  
4. Individuals with normal office BP but elevated BP on 
ABPM were described as those with masked white coat 
hypertension (WCH). 
 All study participants had resting echocardiographic 
study performed on them using an Aloka SSD-4000 (2004) 
echocardiography machine following the established standard 
technique and parameters by the American Society of 
Echocardiography (ASE) recommendations. (Henry et al., 
1980). 
 A two‐dimensionally guided M‐mode echocardiogram 
was performed on each participant at the same visit by a single 
Cardiologist, who was blinded to their BP status. Accurate 
linear measurements of interventricular septal wall thickness, 
posterior wall thickness, and LV internal dimensions, 
including end‐diastolic/systolic diameters were obtained. Left 
ventricular mass index (LVMI) was calculated by Devereux's 
formula. (Devereux, 1987). The geometric classification was 
defined by the combination of increased relative wall 
thickness (RWT) and LVH (LVMI >115 g/m2 for men, >95 
g/m2 for women) at end diastole. Ejection fraction, mitral 
pulse‐wave Doppler E/A ratio (Em/Am), deceleration time, 
and isovolumetric relaxation time were estimated with two‐
dimensional (2-D) echocardiography. 
 
Ethical consideration: Ethical approval was granted by the 
Ethical Review Committee of the University of Ilorin 
Teaching Hospital, Ilorin, Nigeria. Approval number: ERC 
PAN/2014/05/1302c. 
 
Statistical analysis:  Analysis of the data was done using 
SPSS 20. Quantitative and qualitative demographic 
characteristics were summarized and presented in tabular 
forms. Data were expressed as mean ± standard deviation (SD) 
while frequencies were expressed as percentages. The Student 
t-test was used to compare the means of continuous variables 
between two groups that were normally distributed. Chi-
square was used to compare proportions. The results were 
presented as the odds ratio with corresponding 95% 
confidence interval. For all tests, statistical significance was 
set at a p-value < 0.05. 
 
White coat hypertension and left ventricular hypertrophy 
95 Afr. J. Biomed. Res. Vol. 24, No.1 (January) 2021  Dele-Ojo et al 
RESULTS  
 
The demographic, anthropometric and clinical 
characteristics of the study population. 
A total of 88 participants consisting of 44 patients with WCH 
and 44 age and sex-matched normotensive controls were 
studied. Twenty-seven (27) of the participants in each group 
were females. Age range for both groups was 18–75years, the 
mean age was 43.3 + 11.4 years and 43.6 + 9.4 years for those 
WCH and control respectively. Participants with WCH had 
significantly higher weight, BMI, office SBP, and office DBP  
 All the ambulatory blood pressure of the WCH were 
significantly higher than the control group. However, the day-
time pulse rate was similar in both groups, as shown in Table 
2. The echocardiographic parameters in both groups were also 
similar. 24 of the WCH group and 19 of the control group had 
LVH, with no statistical difference between both groups, as 
shown in Table 3. 
 
 
Table 1:  
The demographic, anthropometric and clinical parameters of the 
study participants. 





Male, n 17 17 0.897 
Female,n 27 27  
Age (years) 43.3±11.4  43.6±9.4 0.897 
Weight (kg) 73.3±13.0 65.3±12.2  0.004* 
Height (cm) 1.67±0.08  1.66±0.09 0.569 
BMI (kg/m2) 26.4±4.5   23.8±4.3 0.008* 
WC (cm) 87.3±15.4 83.5±11.3 0.192 
HC (cm) 97.9±13.3 96.1±10.2 0.492 
Waist-Hip ratio 0.89±0.13 0.87±0.06 0.240 
Pulse rate (bpm) 80.5±13.2 75.3±11.8 0.468 
Office SBP (mmHg) 144.2±12.2 117.0±11.7 <0.001* 
Office DBP (mmHg) 88.3±10.3                              72.3±9.6                    <0.001* 
Key: *= Statistically significant, n= number, SD = Standard 
deviation, BMI = Body mass index, WC = Waist circumference, HC 
= Hip circumference, SBP = Systolic blood pressure, DBP = 
Diastolic blood pressure, b.p.m = beats per minute. 
 
 
Table 2:  
Ambulatory blood pressure indices of the participants with WCH 
and Control. 






24-hr SBP (mmHg) 123.3±5.9 116.9±7.7 <0.001* 
24-hr DBP (mmHg)        73.0±5.1 69.1±6.8 0.003* 
Day-time SBP (mmHg) 124.5±6.0 118.9±8.3 <0.001* 
Day-time DBP (mmHg) 74.5±5.3  70.8±7.0  <0.001* 
Night-time SBP (mmHg) 118.6±8.5 109.5±8.3 <0.001* 
Night-time DBP (mmHg) 69.2±5.7  62.3±7.0 <0.001* 
Day-time pulse rate(bpm) 79.4±9.2   79.4±9.2 0.988 
Day-time pulse pressure 
(mmHg) 
50.3±6.5 46.7±6.1 0.059 
Key: * statistically significant, WCH, White coat 
hypertension; SBP, Systolic blood pressure; DBP, Diastolic 
blood pressure, n=number. 
 
 
Table 3:  
The echocardiographic parameters of the participants with 
WCH and normal blood pressure. 




AOD (cm) 2.83±0.23 2.77±0.32 0.374 
LAD (cm)        3.36±0.54 3.34±0.47 0.888 
LVDd (cm) 4.55±0.42 4.57±0.64 0.860 
LVDs (cm) 2.90±0.34  2.93±0.57  0.800 
LVM (g) 227.14±64.17 211.76±89.64 0.359 
LVMI (g/m2) 122.66±31.10 119.48±40.93 0.683 
EF (%) 65.73±6.86 66.23±7.40 0.743 
Mitral E/A 1.24±0.46 1.38±0.43 0.138 
DT (ms) 183.02±71.41 196.23±79.07 0.113 
IVRT (ms) 105.70±17.07 98.95±22.12  0.138 
LVH, n 24 19 0.286 
Key:  
WCH, White coat hypertension;  
SH, Systemic hypertension; SD, Standard deviation;  
BP, Normal blood pressure; AOD, Aortic Opening dimension; LAD, 
Left atrial dimension; LVM, Left ventricular mass; LVMI, Left 
ventricular mass index;  
RWT, Relative wall thickness; EF, Ejection fraction;  
DT, Deceleration time; IVRT, Isovolumetric relaxation time, LVH, 




This study showed high but similar prevalence of LVH in both 
the WCH and normotensive groups as 24 individuals with 
WCH and 19 of the normotensive individuals had LVH. 
Additionally, in this study, both WCH and normotensive 
groups showed similar cardiac structures, as there was no 
significant difference in their left ventricular mass, left 
ventricular mass index and left atrial diameter values. 
Previous studies on the association between white-coat 
hypertension and left ventricular hypertrophy (LVH) in WCH 
have shown conflicting results.(Cuspidi et al., 2018, Huang et 
al., 2017, Franklin et al., 2013, Staessen et al., 1999, 
Pierdomenico et al., 1995, Parati et al., 2000a). There has been 
documented evidence of intermediate risk of subclinical target 
organ damage between normotension and sustained 
hypertension. These findings are in tandem with the findings 
(Verdecchia et al., 1999) that showed the prevalence of LV 
hypertrophy and LV mass were similar in their study 
population of with WCH and normotension. Another study 
equally showed similar cardiac structure in 18 normotensive 
and 18 white coat hypertensive individuals (White et al., 
1989).  Also, white coat hypertensives were shown to have 
similar cardiovascular risk as their normotensive controls. 
(Hoegholm et al., 1993). However, increased left ventricular 
mass index were reported among Nigerians with high normal 
BP in comparison with those with optimal BP (Saidu et al., 
2018). Also, the results of the recently performed meta-
analyses provide evidence that white-coat hypertension is 
characterized, at cardiac level, by an increase in left 
ventricular mass index and greater values of left atrial 
diameter (Cuspidi et al., 2015). Accounting for the different 
findings between these later studies and our study could be the 
relatively small sample size used in our study. 
 Worthy of note in our study, participants with WCH 
display increased body mass index which has also being 
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previously documented. (Brady, 2016, Dele-Ojo et al., 2019). 
Metabolic alterations in combination with elevated office 
blood pressure and increased blood pressure variability 
contribute to the development of subclinical target organ 
damage at cardiac, vascular and renal level. (Sega et al., 2001, 
Brady, 2016). This could account for the occurrence of LVH 
in our study population. Obesity is associated with LVH 
irrespective of blood pressure (Brady, 2016). Elevated BP has 
been implicated in the pathogenesis of left ventricular 
hypertrophy, however, the extent of cardiac growth and 
response to increased pressure loading is not similar among 
patients, thereby suggesting genetic mechanisms in cardiac 
hypertrophy (Simpson et al., 1995). Blacks are known to have 
a greater left ventricular wall thickness and left ventricular 
mass, even with equivalent BP than White patients. (Sharp et 
al., 2008). Furthermore, there were more women in our study 
population as this could account for the high percentage of 
LVH in both groups. Studies have shown that women with 
hypertension are at higher risk of developing LVH than their 
male counterparts with similar BP measurements (Liao et al., 
1995, Wassertheil-Smoller et al., 2004). LVH in women is a 
strong cardiovascular risk factor as it causes an increased 
incidence in atrial fibrillation and sudden death in them. (Liao 
et al., 1995, Wassertheil-Smoller et al., 2004). The 2012 
International Database on Ambulatory Blood Pressure in 
Relation to Cardiovascular Outcomes (IDACO) study also 
revealed that the incidence rate of cardiovascular events in 
participants with untreated WCH was no greater than in the 
untreated population with normotension. (Franklin et al., 
2012). The findings in this study are in tandem with other 
studies that showed that the level of target organ damage is no 
greater than in the normotensive control population. It will be 
nonetheless important to assess every patient with WCH for 
the presence of end organ damage such as LVH and to be 
followed up for the development of other cardiovascular risk 
factors. The PAMELA showed a significantly higher risk of 
new onset diabetes mellitus during a 10- year follow-up in 
untreated white coat hypertensives as compared with 
normotensive individuals (Hoegholm et al., 1993) and 43% of 
WCH had progressed to sustained hypertension. (Sega et al., 
2001) Similarly, in Finland, the relative risk for developing 
sustained hypertension in WCH was almost three times 
greater than the one detected in the normotensive group 
(Hanninen et al., 2012). 
 Therefore, if our study participants are followed up, there 
may be a significant difference in the cardiac structure of the 
WCH and the normotensive control. There is therefore need 
for patients’ education as regard increased cardiovascular 
risks, with a special emphasis on maintaining optimal weight. 
In the absence of additional cardiovascular risk factors, 
intervention may be limited to lifestyle changes but should 
also include meticulous follow-up because people with WCH 
have a greater risk of progressing to SH (Hoegholm et al., 
1993). 
 In conclusion, there is high but similar prevalence of LVH 
among participants with WCH and normotension among adult 
Nigerians. Hence, there is need to assess every patient with 
WCH for the presence of LVH and to be followed up for the 
development of other cardiovascular risk factors. 
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